Symbols

AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial

LMAT

Lemaitre Vascular·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 0

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LMAT

Lemaitre Vascular, Inc.

A provider of devices, implants and services for the treatment of peripheral vascular disease

Industry

Medical instruments

Established Date

11/28/1983

Listing Date

10/19/2006

Exchange

NASDAQ Stock Exchange

Full-time Employees

655

Fiscal Year Ends

12-31

Website

www.lemaitre.com

Security Type

Common stock

Office address

63 Second Avenue , Burlington , Massachusetts 01803

Business

Provides medical devices and human tissue cryopreservation services.

Introduction

Founded on November 28, 1983, Lemaitre Vascular, Inc., is a global supplier of medical devices and implants for the treatment of peripheral vascular diseases. The company develops, manufactures and sells a range of vascular devices designed to meet the needs of vascular surgeons as well as cardiac, general and neurosurgeons. The company offers a diversified portfolio of branded products, which are widely recognized among vascular professionals, and its main products are sold globally, mainly in the United States, Europe, Canada and Asia Pacific. The company operates from its global headquarters in Burlington, Massachusetts, and has added sales offices in North America, Europe and Asia Pacific. About 95 percent of its net sales are generated through its direct sales team.

Company Financials

EPS

LMAT has released its 2026 Q2 earnings. EPS was reported at 0.74, versus the expected 0.81, missing expectations. The chart below visualizes how LMAT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LMAT has released its 2026 Q2 earnings report, with revenue of 70.38M, reflecting a YoY change of 9.57%, and net profit of 17.05M, showing a YoY change of 23.74%. The Sankey diagram below clearly presents LMAT's revenue sources and cost distribution.